Track topics on Twitter Track topics that are important to you
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that its Chief Executive Officer George E. Anastassov, MD, DDS, MBA, will speak at the The Money Show Dallas about emerging cannabis markets and in particular the cannabis drug market. The Money Show Dallas, taking place from Oct. 19-21 at the Hyatt Regency in Dallas, is a conference for investors and traders in search of opportunities for diversification and profits across the globe.
Dr. Anastassov will present, “The Cannabis Drug Market & Emerging Markets” on Friday, October 21, at 2:00 p.m., an in-depth discussion about the latest intelligence available for investors to learn and profit from opportunities in today’s market. Dr. Anastassov will speak to investors in attendance about the value of cannabinoids and hemp derivatives, including how AXIM Biotech is using cannabinoids (both synthetic and natural) in the Company’s extensive line of pharmaceutical, nutraceutical, consumer and alternative energy products.
“I’m looking forward to speaking to potential investors about the plethora of opportunities the cannabinoid-based drug market holds and explaining how our Company is using these compounds to find answers for health conditions with no known answers,” said Dr. Anastassov. “Cannabis is currently being used mostly empirically to treat a number of conditions and diseases without much clinical evidence. AXIM has a pipeline of patent issued and pending cannabis-based compounds in pre- and clinical trials that I am looking forward to inform the audience about.”
The founders and officers of AXIM® Biotech are the inventors of CanChew®, the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of cannabidiol (CBD). AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally.
In addition, AXIM® Biotech created a pharmaceutical breakthrough invention with the world’s first patented cannabinoid controlled-release CBD/THC (cannabidiol/tetrahydrocannabinol) chewing gum: MedChew Rx™. In clinical trials for pain and spasticity associated with MS, as featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for MS, the Reuters article conveys the potential for MedChew Rx™ at an estimated $4.8 billion USD. MedChew Rx™ is on track to be fully registered by the EMA and FDA.
Another AXIM® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis. AXIM® Biotech’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.
AXIM® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell, and distribute hemp-based products.
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 email@example.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...